Overview

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Status:
RECRUITING

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 positive tumors who received prior anti-programmed cell death 1 (PD-1)/PD-L1 inhibitor in early setting

Phase:

PHASE3

Details

Lead Sponsor:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Treatments:

130-nm albumin-bound paclitaxel
Capecitabine
Carboplatin
eribulin
Paclitaxel